Filing Analysis
Regulation FD Disclosure
Filed May 07, 2026
LOW
Voyager Therapeutics announced its first quarter 2026 financial results and provided general corporate updates. The announcement was made via a press release furnished as Exhibit 99.1.
Key Facts
- Announcement of Q1 2026 financial results on May 7, 2026.
- Corporate updates provided in conjunction with financial results.
- Filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
- The report was signed by CEO Alfred Sandrock, M.D., Ph.D.
Officer Departure
Filed Apr 21, 2026
MEDIUM
Voyager Therapeutics announced the resignation of CFO Nathan Jorgensen, Ph.D., effective May 8, 2026. The company has appointed current COO Robin Swartz as Principal Financial Officer and VP of Finance Amy Quinlan as Principal Accounting Officer to assume his responsibilities.
Key Facts
- Nathan Jorgensen, Ph.D. resigned as CFO on April 15, 2026, effective May 8, 2026, to pursue a new opportunity.
- Robin Swartz, age 55, currently the COO and Chief Business Officer, will become the Principal Financial Officer and Treasurer.
- Amy Quinlan, age 51, currently VP of Finance, will become the Principal Accounting Officer.
- The company stated there were no disagreements with Dr. Jorgensen regarding operations, policies, or practices.
- Robin Swartz has over 10 years of finance experience at Sanofi Genzyme prior to joining Voyager.
Other SEC Filing
Filed Mar 09, 2026
LOW
Voyager Therapeutics reported its fourth quarter and full year 2025 financial results and provided corporate updates on March 9, 2026.
Key Facts
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The report covers the fiscal period ending December 31, 2025.
- A press release detailing the financial and operating results was furnished as Exhibit 99.1.
- The report was signed by CEO Alfred Sandrock, M.D., Ph.D.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.